Locations:
SearchAdvertisement
Will avelumab plus cabozatinib outperform avelumab monotherapy as maintenance treatment?
Understanding cell growth dynamics may be key to controlling therapeutic resistance
A New Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma
Improving safety, efficacy and access for emerging therapies
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Phase 2 study of parsaclisib with ruxolitinib demonstrates improved efficacy for patients previously treated with ruxolitinib alone
Dr. Aaron Gerds argues for more balance in safety reporting
DESTINY-Breast04 study leads to practice-changing findings
Notable research chosen by Cleveland Clinic Cancer Center staff
Largest real-world cohort of polycythemia vera patients
Treatment effective post-ruxolitinib failure
Advertisement
Advertisement